Could a malaria drug ease lingering lyme symptoms?
NCT ID NCT07230028
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether adding hydroxychloroquine (a malaria drug) to standard doxycycline treatment can reduce long-term complaints in adults with Lyme disease. Fifty participants will take either hydroxychloroquine or a placebo twice daily for 28 days, with follow-up visits over a year. The goal is to see if the combination improves quality of life and physical symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TREATMENT LYME DISEASE SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxychloroquine (Plaquenil) added to doxycycline
What this could lead to
If it works, this could point toward a better treatment for lingering Lyme symptoms, improving quality of life for patients.
What could go wrong
This is a small pilot study with only 50 people, so results may not apply widely. The treatment is short-term and may not help everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.